Genta Incorporated announced the completion of patient enrollment into AGENDA, a Phase 3 trial of Genasense (oblimersen sodium) injection in patients with advanced melanoma. This randomized, double-blind, placebo-controlled trial has enrolled 315 melanoma patients with low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood. The study was designed to confirm certain safety and efficacy results obtained in a prior randomized trial (known as GM301) of Genasense combined with dacarbazine (DTIC) in chemotherapy-naïve patients.
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment.
For more information call (908) 286-9800 or visit www.genta.com.